DRG Market Assessment reports
Access comprehensive market intelligence covering Disease Landscape & Forecast, Epidemiology Intelligence, Biosimilars Intelligence, China In-depth and more.
Chronic Obstructive Pulmonary Disease | Unmet Need | Severe to Very Severe | US EU | 2025
The severe to very severe chronic obstructive pulmonary disease (COPD) drug market is becoming increasingly crowded as several LAMAs, LABA/ICSs, LABA/LAMAs, LABA/LAMA/ICSs, and, most recently, the…
Breast Cancer – Unmet Need – Unmet Need – Metastatic Triple-Negative Breast Cancer (US/EU)
The treatment of metastatic triple-negative breast cancer is rapidly evolving with new combination therapies and biomarker-driven approaches. Immunotherapies such as Keytruda (Merck & Co.) have…
Parkinson’s Disease – Unmet Need – Unmet Need – Levodopa-Induced Dyskinesia (US/EU)
Levodopa-induced dyskinesia (LID) is a complication stemming from the long-term use of levodopa to treat Parkinson’s disease (PD); it causes abnormal involuntary movements. Surveyed neurologists…
Multiple Sclerosis – Current Treatment – Current Treatment: Physician Insights – Multiple Sclerosis (EU5)
Numerous disease-modifying therapies (DMTs) have entered the multiple sclerosis (MS) disease landscape in recent years, many of them next-generation alternatives within existing classes. Most…
Atopic Dermatitis / Atopic Eczema – Unmet Need – Unmet Need – Moderate to Severe Topical-Refractory Atopic Dermatitis (US/EU)
Topical therapies such as corticosteroids and calcineurin inhibitors are the mainstay of treatment of atopic dermatitis; however, for patients with moderate to severe disease, topical options are…
